Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin plus antibiotics for prevention of hepatorenal syndrome and death in cirrhosis with non-SBP bacterial infections
NL-OMON42187Phase 4Withdrawn
- Sponsor
- European Foundation for the Study of Chronic Liver Failure
- Start
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of albumin (human) in Cirrhosis and bacterial disease (2 arms), sponsored by European Foundation for the Study of Chronic Liver Failure. Primary endpoints: Hospital survival and 28-day survival. Planned start Oct 2015; status: withdrawn.
02
Drugs
albumin (human)
03
Conditions
Cirrhosisbacterial disease
Beyond the preview
Go deeper on NL-OMON42187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42187.